These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
136 related articles for article (PubMed ID: 16534016)
21. Recommendations for use of everolimus after heart transplantation: results from a Latin-American Consensus Meeting. Bocchi EA; Ahualli L; Amuchastegui M; Boullon F; Cerutti B; Colque R; Fernandez D; Fiorelli A; Olaya P; Vulcado N; Perrone SV Transplant Proc; 2006 Apr; 38(3):937-42. PubMed ID: 16647515 [TBL] [Abstract][Full Text] [Related]
22. Conversion to everolimus in maintenance patients--current clinical strategies. Pohanka E Nephrol Dial Transplant; 2006 Jul; 21 Suppl 3():iii24-9. PubMed ID: 16815853 [TBL] [Abstract][Full Text] [Related]
23. Demystifying the new drug application. Scheindlin S Mol Interv; 2004 Aug; 4(4):188-91. PubMed ID: 15304553 [No Abstract] [Full Text] [Related]
24. Avoidance of calcineurin inhibitors with use of proliferation signal inhibitors in de novo heart transplantation with renal failure. González-Vílchez F; de Prada JA; Exposito V; García-Camarero T; Fernández-Friera L; Llano M; Ruano J; Martín-Durán R J Heart Lung Transplant; 2008 Oct; 27(10):1135-41. PubMed ID: 18926406 [TBL] [Abstract][Full Text] [Related]
25. Comparison of the Innofluor certican assay with HPLC-UV for the determination of everolimus concentrations in heart transplantation. Baldelli S; Crippa A; Gabrieli R; Fiocchi R; Perico N; Merlini S; Ottomano C; Cattaneo D Clin Biochem; 2006 Dec; 39(12):1152-9. PubMed ID: 17054930 [TBL] [Abstract][Full Text] [Related]
27. Possible role of everolimus in improving renal function in long-term heart transplantation. Fiocchi R; Iacovoni A; Sebastiani R; Fontana A; Gandolfi L; Gamba A Transplant Proc; 2007; 39(6):1967-9. PubMed ID: 17692667 [TBL] [Abstract][Full Text] [Related]
28. Applications for approval to market a new drug; complete response letter; amendments to unapproved applications. Final rule. Food and Drug Administration, HHS Fed Regist; 2008 Jul; 73(133):39588-611. PubMed ID: 18850675 [TBL] [Abstract][Full Text] [Related]
29. New drug applications and abbreviated new drug applications; technical amendment. Final rule; technical amendment. Food and Drug Administration, HHS Fed Regist; 2009 Mar; 74(43):9765-6. PubMed ID: 19418639 [TBL] [Abstract][Full Text] [Related]
30. Expanded access to investigational drugs for treatment use. Final rule. Food and Drug Administration, HHS Fed Regist; 2009 Aug; 74(155):40900-45. PubMed ID: 19691173 [TBL] [Abstract][Full Text] [Related]
31. New advances in antirejection therapy. Chan M; Pearson GJ Curr Opin Cardiol; 2007 Mar; 22(2):117-22. PubMed ID: 17284990 [TBL] [Abstract][Full Text] [Related]
32. Multicenter trial of everolimus in pediatric renal transplant recipients: results at three year. Ettenger R; Hoyer PF; Grimm P; Webb N; Loirat C; Mahan JD; Mentser M; Niaudet P; Offner G; Vandamme-Lombaerts R; Hexham JM; Pediatr Transplant; 2008 Jun; 12(4):456-63. PubMed ID: 18466433 [TBL] [Abstract][Full Text] [Related]
33. Potential pathways for abbreviated approval of generic biologics under existing law and proposed reforms to the law. Dinh TQ Food Drug Law J; 2007; 62(1):77-137. PubMed ID: 17444027 [No Abstract] [Full Text] [Related]
34. Sirolimus: mammalian target of rapamycin inhibitor to prevent kidney rejection. Cowan PA; Heizer KE Nephrol Nurs J; 2000 Dec; 27(6):623-5. PubMed ID: 16649344 [TBL] [Abstract][Full Text] [Related]
36. Drug approval and pharmaceutical pricing. Kozma CM Manag Care Interface; 2002 Feb; 15(2):65-6. PubMed ID: 11875964 [No Abstract] [Full Text] [Related]
37. Conversion from a calcineurin inhibitor to everolimus therapy in maintenance liver transplant recipients: a prospective, randomized, multicenter trial. De Simone P; Metselaar HJ; Fischer L; Dumortier J; Boudjema K; Hardwigsen J; Rostaing L; De Carlis L; Saliba F; Nevens F Liver Transpl; 2009 Oct; 15(10):1262-9. PubMed ID: 19790150 [TBL] [Abstract][Full Text] [Related]
38. [Use of Sirolimus in five pediatric patients undergoing solid organ transplantation]. Roque E J; Ríos M G; Vignolo A P; Pinochet V C; Schultz M; Humeres A R; Delucchi A; Rius A M; Hepp K J Rev Med Chil; 2008 May; 136(5):631-6. PubMed ID: 18769812 [TBL] [Abstract][Full Text] [Related]
39. Long-term results of kidney transplantation with cyclosporine- and everolimus-based immunosuppression. Iaria G; Pisani F; Iorio B; Lucchesi C; De Luca L; Ielpo B; D'Andria D; Tariciotti L; Tisone G Transplant Proc; 2006 May; 38(4):1018-9. PubMed ID: 16757249 [TBL] [Abstract][Full Text] [Related]
40. Comparison of fluorescent polarization immunoassay (FPIA) versus HPLC to measure everolimus blood concentrations in clinical transplantation. Khoschsorur G; Fruehwirth F; Zelzer S; Stettin M; Halwachs-Baumann G Clin Chim Acta; 2007 May; 380(1-2):217-21. PubMed ID: 17320846 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]